Intra-Cellular Therapies Aktie
WKN DE: A1XDTL / ISIN: US46116X1019
|
03.08.2026 14:46:53
|
Helus Pharma Appoints Michael Halstead CEO, Effective Immediately
(RTTNews) - On Monday, Cybin D/B/A Helus Pharma (HELP) announced that it has appointed Michael Halstead as Chief Executive Officer, effective immediately.
Halstead brings 25 years of industry experience, most recently serving as President of Intra-Cellular Therapies, Inc. (ITCI).
Before Intra-Cellular, Halstead was a senior leader at Warner Chilcott plc.
In the pre-market activity on the Nasdaq, the shares were trading 0.90 percent lower at $7.75, after closing Friday's closing 3.93 percent down
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Intra-Cellular Therapies Inc
| Keine Nachrichten verfügbar. |
Analysen zu Intra-Cellular Therapies Inc
Aktien in diesem Artikel
| Cybin Inc Registered Shs | 7,85 | 16,12% |
|